Who makes Jincaopian Tablets low dose?

Jincaopian Tablets low dose is developed by Beijing Konruns Pharmaceutical Co., Ltd..

What development phase is Jincaopian Tablets low dose in?

Jincaopian Tablets low dose is in Phase 2.

Last reviewed 2026-05-14 · How we verify

Jincaopian Tablets low dose

Beijing Konruns Pharmaceutical Co., Ltd. · Phase 2 active Small molecule

At a glance

Generic name	Jincaopian Tablets low dose
Also known as	ZY5301
Sponsor	Beijing Konruns Pharmaceutical Co., Ltd.
Modality	Small molecule
Phase	Phase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

The Effect of Jincaopian Tablets on Chronic Pelvic Pain After Pelvic Inflammatory Disease (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Jincaopian Tablets low dose CI brief — competitive landscape report
Jincaopian Tablets low dose updates RSS · CI watch RSS
Beijing Konruns Pharmaceutical Co., Ltd. portfolio CI